메뉴 건너뛰기




Volumn 68, Issue SUPPL. 13, 2007, Pages 16-19

Narcolepsy: Treatment issues

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ATOMOXETINE; CLOMIPRAMINE; DESIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; IMIPRAMINE; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; OXYBATE SODIUM; PEMOLINE; PLACEBO; PROTRIPTYLINE; SELEGILINE; VENLAFAXINE;

EID: 37349077001     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (8)

References (10)
  • 1
    • 20444414825 scopus 로고    scopus 로고
    • Emerging therapies in narcolepsy-cataplexy
    • Mignot E, Nishino S. Emerging therapies in narcolepsy-cataplexy. Sleep 2005;28:754-763
    • (2005) Sleep , vol.28 , pp. 754-763
    • Mignot, E.1    Nishino, S.2
  • 2
    • 34248149838 scopus 로고    scopus 로고
    • Clinical and neurobiological aspects of narcolepsy
    • Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med 2007;8:373-399
    • (2007) Sleep Med , vol.8 , pp. 373-399
    • Nishino, S.1
  • 3
    • 0035877168 scopus 로고    scopus 로고
    • Practice parameters for the treatment of narcolepsy: An update for 2000
    • Littner M, Johnson SF, McCall WV, et al. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 2001;24:451-466
    • (2001) Sleep , vol.24 , pp. 451-466
    • Littner, M.1    Johnson, S.F.2    McCall, W.V.3
  • 4
    • 0027745834 scopus 로고
    • Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds
    • Nishino S, Arrigoni J, Shelton J, et al. Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep 1993;16:706-712
    • (1993) Sleep , vol.16 , pp. 706-712
    • Nishino, S.1    Arrigoni, J.2    Shelton, J.3
  • 5
    • 0038178414 scopus 로고    scopus 로고
    • A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy
    • US Xyrem Multicenter Study Group
    • US Xyrem Multicenter Study Group. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003;26:31-35
    • (2003) Sleep , vol.26 , pp. 31-35
  • 6
    • 33845473047 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy
    • Xyrem International Study Group
    • Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1:391-397
    • (2005) J Clin Sleep Med , vol.1 , pp. 391-397
  • 7
    • 16644364531 scopus 로고    scopus 로고
    • Sodium oxybate for excessive daytime sleepiness in narcolepsy-cataplexy
    • Arnulf I, Mignot E. Sodium oxybate for excessive daytime sleepiness in narcolepsy-cataplexy. Sleep 2004;27:1242-1243
    • (2004) Sleep , vol.27 , pp. 1242-1243
    • Arnulf, I.1    Mignot, E.2
  • 8
    • 37349130863 scopus 로고    scopus 로고
    • Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2005
    • Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2005
  • 9
    • 0025734373 scopus 로고
    • Relative efficacy of drugs for the treatment of sleepiness in narcolepsy
    • Mitler MM, Hajdukovic R. Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep 1991;14:218-220
    • (1991) Sleep , vol.14 , pp. 218-220
    • Mitler, M.M.1    Hajdukovic, R.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.